<div id="readability-page-1"><p>Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) have received an average rating of &#34;Moderate Buy&#34; from the nineteen ratings firms that are currently  covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and seventeen have issued  a buy rating on  the company. The average 12 month price target among brokerages that have covered the stock in the last year is $1,017.67.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>Which Healthcare Stock Is the Best Buy Right Now?</li></ul><p>A number of equities analysts have recently weighed in on LLY shares. Berenberg Bank  set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Morgan Stanley lowered their price target on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday. Truist Financial increased their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, February 3rd. Wells Fargo &amp; Company boosted their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an &#34;overweight&#34; rating in a research report on Wednesday, March 5th. Finally, The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and cut their price target for the company from $892.00 to $888.00 in a report on Tuesday.</p><p><b>Check Out Our Latest Analysis on Eli Lilly and Company</b></p><h2>Insiders Place Their Bets</h2><ul><li>Price Targets Show These 3 Stocks Near the $1 Trillion Mark</li></ul><p>In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own  0.13% of the company's stock. </p><h2>Institutional Investors Weigh In On Eli Lilly and Company</h2><p>Several institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC raised its position in  Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after purchasing an additional 14,852,076 shares in the last quarter.  Norges Bank acquired a new position in shares of  Eli Lilly and Company in the 4th quarter worth approximately $8,407,908,000.  Proficio Capital Partners LLC lifted its position in shares of  Eli Lilly and Company by 100,387.1% during the 4th quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock worth $4,016,110,000 after buying an additional 5,197,038 shares during the period.  Wellington Management Group LLP boosted its stake in  Eli Lilly and Company by 19.0% in the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after buying an additional 2,012,129 shares in the last quarter.  Finally, Capital International Investors grew its position in  Eli Lilly and Company by 23.2% in the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after acquiring an additional 1,645,222 shares during the period. Institutional investors own  82.53% of the company's stock. </p><h2>Eli Lilly and Company Stock Down 4.5 %</h2><ul><li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li></ul><p>Shares of Eli Lilly and Company stock opened at $719.85 on Friday. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a market cap of $682.54 billion, a P/E ratio of 61.47, a P/E/G ratio of 1.40 and a beta of 0.51. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The stock has a 50-day moving average price of $838.96 and a 200 day moving average price of $824.81. </p><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%.  As a group, analysts expect that  Eli Lilly and Company will post 23.48 EPS for the current fiscal year. </p><h2>Eli Lilly and Company Company Profile</h2> (Get Free Report<p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>Trading Halts Explained</li><li>Joby Aviation: Operational Momentum vs. Market Sentiment</li><li>3 REITs to Buy and Hold for the Long Term</li><li>Broadcom's Big Outperformance Shows Strength Amid Tariff Decline</li><li>Roth IRA Calculator: Calculate Your Potential Returns</li><li>Carvana: Can Turnaround Strength Outdrive Market Headwinds?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Eli Lilly and Company (NYSE: LLY) has received an average rating of "Moderate Buy" from 19 brokerages. Analysts have set a 12-month price target averaging $1,017.67, with two hold ratings and seventeen buy ratings. Recent price targets include $970.00 from Berenberg Bank and $1,100.00 from Wells Fargo. The stock opened at $719.85, with a 1-year low of $677.09 and a high of $972.53. Institutional investors own 82.53% of the company, and Eli Lilly reported $5.32 EPS for the last quarter, missing estimates by $0.13.</p>

Eli Lilly and Company (NYSE:LLY) Receives Average Recommendation of "Moderate Buy" from Brokerages